Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AGER | Q15109 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179567 | 0.91 | ADORA2A (0.55) | ADORA2ACYP2C9GCKKCNH2MAPT | |
| SCHEMBL2177990 | 0.90 | ADORA2A (0.60) | ADORA2ACYP2C19GCKKCNH2 | |
| SCHEMBL2176499 | 0.89 | ADORA2A (0.62) | ADORA2ACYP2C9CYP2C19GCKNPC1 | |
| SCHEMBL2176230 | 0.89 | AGER (0.57) | ADORA2ACYP2C9CYP2C19GCKKCNH2 | |
| SCHEMBL2178536 | 0.88 | RAB9A (0.51) | ADORA2ACYP2C9GCKKCNH2POLB | |
| SCHEMBL2178415 | 0.87 | SCN3A (0.49) | ADORA2ACYP2C9CYP2C19GCKNPC1 | |
| SCHEMBL2177412 | 0.87 | KCNK3 (0.53) | ADORA2ACYP2C9CYP2C19GCKPOLB | |
| SCHEMBL2179714 | 0.86 | AURKA (0.50) | ADORA2ACYP2C9CYP2C19GCKPOLB | |
| SCHEMBL2178887 | 0.86 | ADORA2A (0.46) | ADORA2ACYP2C9CYP2C19GCKPOLB | |
| SCHEMBL2180846 | 0.85 | MAPT (0.49) | ADORA2ACYP2C9CYP2C19GCKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | claimed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | claimed |
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | GCK, GCKR, HK1 | ADORA2A 1685/4885CYP2C9 2499/4885CYP2C19 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.